Biomarkers in atopic dermatitis-a review on behalf of the International Eczema Council

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

卷:147

Review

Renert-Yuval, Yael¹  Thyssen, Jacob P.²  Bissonnette, Robert³  Bieber, Thomas⁴  Kabashima, Kenji⁵  Hijnen, DirkJan⁶  Guttman-Yassky, Emma⁷ 

[1] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA

[2] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark

[3] Innovaderm Res, Dept Dermatol, Montreal, PQ, Canada

[4] Univ Bonn, Dept Dermatol & Allergy, Christine Kuhne Ctr Allergy Res & Educ, Bonn, Germany

[5] Kyoto Univ, Dept Dermatol, Sch Med, Kyoto, Japan

[6] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands

[7] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY USA

关键词: Atopic dermatitis;    biomarker;    International Eczema Council;    CCL17/TARC;    IgE;    eosinophils;    CCL22/MDC;    CCL26/eotaxin-3;    CCL27/CTACK;    CCL18/pulmoncuy and activation-regulated chemokine;    IL-13;    IL-22;   

DOI  :  10.1016/j.jaci.2021.01.013

来源: Elsevier

【 摘 要 】

Atopic dermatitis (AD) is a common yet complex skin disease, posing a therapeutic challenge with increasingly recognized different phenotypes among variable patient populations. Because therapeutic response may vary on the basis of heterogeneous clinical and molecular phenotypes, a shift toward precision medicine approaches may improve AD management. Herein, we will consider biomarkers as potential instruments in the toolbox of precision medicine in AD and will review the process of biomarker development and validation, the opinion of AD experts on the use of biomarkers, types of biomarkers, encompassing biomarkers that may improve AD diagnosis, biomarkers reflecting disease severity, and those potentially predicting AD development, concomitant atopic diseases, or therapeutic response, and current practice of biomarkers in AD. We found that chemokine C-C motif ligand 17/thymus and activation-regulated chemokine, a chemoattractant of T(H)2 cells, has currently the greatest evidence for robust correlation with AD clinical severity, at both baseline and during therapy, by using the recommendations, assessment, development, and evaluation approach. Although the potential of biomarkers in AD is yet to be fully elucidated, due to the complexity of the disease, a comprehensive approach taking into account both clinical and reliable, AD-specific biomarker evaluations would further facilitate AD research and improve patient management.

【 授权许可】

Free